Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Dasatinib Promotes the Maturation of Healthy Donors and Chronic Myelogenous Leukemia Patients Derived Dendritic Cells

Wangjun Cao, Lin He, Hong Zheng, MDPhD, Xiaobing Huang, Xi Yang, Xiaodong WANG, MD, Jingying Dai, PhD

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-138462

Published: 2020

Journal Articles

The Increase on Th1 and CD8+T Levels While a Decrease on Treg Level after Dasatinib Treatment Indicate a Better Therapeutic Response to Dasatinib and Deeper Clinical Remission in Chronic Myelogenous Leukemia Patients

Jingying Dai, PhD, Hong Zheng, MD PhD, Xiaobing Huang, Xi Yang, Xiaodong WANG, MD

Blood (2019) 134 (Supplement_1): 5376.

https://doi.org/10.1182/blood-2019-128413

Published: 2019

Journal Articles

Complementary Transplantation Improved Results of Both Peripheral Blood Stem Cells and Unrelated Cord Blood Transplants in Thalassemia: A Multi-Center Study from China

Chunfu Li, MD, Sixi Liu, MD PhD, Yuelin He, MD, Xiaodong Wang, MD, Jianyun Liao, MD, Shan Li, MD, Xiaolin Zheng, MD, Xuedong Wu, MD PhD, Changgang Li, MD, Xiaoqin Feng, Feiqiu Wen, MD PhD, Huaying Liu, MD, Xiaohui Zhou, MD, Zhiyong Peng, MD, Lan He, MD, Chaoke Bu, MD, Leung Wing, MD PhD

Blood (2019) 134 (Supplement_1): 4617.

https://doi.org/10.1182/blood-2019-129697

Published: 2019

Journal Articles

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Jingying Dai, PhD, Xi Yang, Xiaobing Huang, Hong Zheng, MD PhD, Xiaodong Wang, MD

Blood (2018) 132 (Supplement 1): 4272.

https://doi.org/10.1182/blood-2018-99-113032

Published: 2018

Journal Articles

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

Xi Yang, Hong Zheng, MD PhD, Jingying Dai, PhD, Chenglong Li, MDand PhD, Rong Zhang, MD PhD, Xiaodong WANG, MD, Chunsen Wang, MD, Xiaobing Huang

Blood (2018) 132 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2018-99-111671

Published: 2018

Journal Articles

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Yongqian Jia, MD, Bing Xiang, MD, Xiaodong Wang, MD, Jianjun Li, MD, Chuan He, MD, Yi Su, MD, Hong Lu, MD, Ting Niu, MD, Jie Huang, MD, Xinchuan Chen, MD, Xu Cui, MD, Yuping Gong, MD, PhD, Huanling Zhu, MD, Ting Liu, MD

Blood (2011) 118 (21): 3714.

https://doi.org/10.1182/blood.V118.21.3714.3714

Published: 2011

NARROW

Dasatinib Promotes the Maturation of Healthy Donors and Chronic Myelogenous Leukemia Patients Derived Dendritic Cells

The Increase on Th1 and CD8+T Levels While a Decrease on Treg Level after Dasatinib Treatment Indicate a Better Therapeutic Response to Dasatinib and Deeper Clinical Remission in Chronic Myelogenous Leukemia Patients

Complementary Transplantation Improved Results of Both Peripheral Blood Stem Cells and Unrelated Cord Blood Transplants in Thalassemia: A Multi-Center Study from China

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Email alerts

ASH Publications

American Society of Hematology

Dasatinib Promotes the Maturation of Healthy Donors and Chronic Myelogenous Leukemia Patients Derived Dendritic Cells

The Increase on Th1 and CD8+T Levels While a Decrease on Treg Level after Dasatinib Treatment Indicate a Better Therapeutic Response to Dasatinib and Deeper Clinical Remission in Chronic Myelogenous Leukemia Patients

Complementary Transplantation Improved Results of Both Peripheral Blood Stem Cells and Unrelated Cord Blood Transplants in Thalassemia: A Multi-Center Study from China

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only